x

Sagimet Biosciences Inc. (Nasdaq:SGMT)

Health Care/Life Sciences • Biotechnology
CIK 1400118
Company

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Address
155 Bovet Road
Suite 303
San Mateo, California 94402
Employees
10
Stock Info
Close
$6.05
Day Range
5.61 - 6.34
52 Week Range
2.13 - 20.71
Average volume
1.37M
Short Interest
1.56M (02/15/24)
% of Float Shorted
12.83%
Market Cap
$133.6M
Revenue
N/A
Net Income
-$30.5M
2020 Sales Growth
N/A
Rev. per Employee
N/A
P/E Ratio
N/A
EPS
N/A
Yield
N/A
Dividend
N/A
Ex-Dividend Date
N/A
Key Executives
Board Of Directors
Executive Chairman
George W Kemble PhD
President, Chief Executive Officer & Director
David A Happel MBA
Member-Board of Clinical Advisors
Ursula Matulonis
Member-Board of Clinical Advisors
Johann Bono
Member-Board of Clinical Advisors
Duncan Jodrell
Director
Jinzi J Wu PhD
Independent Director
Elizabeth Grammer
Independent Director
Merdad V Parsey MD, PhD
Independent Director
Richard J Rodgers MBA, CPA
Independent Director
Beth C Seidenberg MD
SEC filings
DateFormEvent
26 Aug, 2024 EFFECT
16 Aug, 2024 8-K
15 Aug, 2024 S-3
14 Aug, 2024 10-Q
14 Aug, 2024 8-K
5 Aug, 2024 4
5 Aug, 2024 3
5 Aug, 2024 3
5 Aug, 2024 4
1 Aug, 2024 8-K
25 Jul, 2024 4
23 Jul, 2024 4
23 Jul, 2024 4
23 Jul, 2024 4
23 Jul, 2024 144
2 Jul, 2024 8-K
13 Jun, 2024 8-K/A
7 Jun, 2024 4
7 Jun, 2024 4
7 Jun, 2024 4
7 Jun, 2024 4
7 Jun, 2024 4
6 Jun, 2024 8-K
23 May, 2024 8-K
15 May, 2024 8-K
15 May, 2024 10-Q
8 May, 2024 3
8 May, 2024 4
6 May, 2024 8-K
18 Apr, 2024 DEF 14A
18 Apr, 2024 DEFA14A
18 Apr, 2024 ARS
3 Apr, 2024 3
3 Apr, 2024 4
3 Apr, 2024 4
3 Apr, 2024 3
28 Mar, 2024 4
25 Mar, 2024 8-K
25 Mar, 2024 10-K
25 Mar, 2024 S-8
11 Mar, 2024 SC 13G/A
14 Feb, 2024 SC 13G
14 Feb, 2024 SC 13G
14 Feb, 2024 SC 13G
14 Feb, 2024 SC 13G
9 Feb, 2024 SC 13G/A
5 Feb, 2024 SC 13G
2 Feb, 2024 8-K
2 Feb, 2024 3
31 Jan, 2024 4
31 Jan, 2024 4
31 Jan, 2024 4
31 Jan, 2024 4
31 Jan, 2024 4
30 Jan, 2024 8-K
29 Jan, 2024 424B4
25 Jan, 2024 EFFECT
24 Jan, 2024 8-K
24 Jan, 2024 S-1/A
23 Jan, 2024 CORRESP
23 Jan, 2024 S-1
23 Jan, 2024 CORRESP
22 Jan, 2024 8-K
16 Jan, 2024 UPLOAD
10 Jan, 2024 DRS
29 Dec, 2023 8-K
8 Dec, 2023 4
21 Nov, 2023 4
21 Nov, 2023 8-K
21 Nov, 2023 4
21 Nov, 2023 4
21 Nov, 2023 4
20 Nov, 2023 4
13 Nov, 2023 8-K
13 Nov, 2023 10-Q
23 Oct, 2023 8-K
27 Sep, 2023 8-K
11 Sep, 2023 SC 13G
8 Sep, 2023 4
21 Aug, 2023 10-Q
21 Aug, 2023 8-K
10 Aug, 2023 8-K
27 Jul, 2023 8-K
20 Jul, 2023 4
20 Jul, 2023 4
20 Jul, 2023 4
20 Jul, 2023 4
20 Jul, 2023 4
20 Jul, 2023 4
20 Jul, 2023 4
20 Jul, 2023 4
20 Jul, 2023 4
20 Jul, 2023 4
20 Jul, 2023 4
20 Jul, 2023 4
20 Jul, 2023 4
18 Jul, 2023 8-K
17 Jul, 2023 S-8
17 Jul, 2023 424B4 IPO completed
14 Jul, 2023 SEC STAFF
13 Jul, 2023 3
13 Jul, 2023 S-1MEF
13 Jul, 2023 3
13 Jul, 2023 3
13 Jul, 2023 3
13 Jul, 2023 3
13 Jul, 2023 3
13 Jul, 2023 3
13 Jul, 2023 3
13 Jul, 2023 3
13 Jul, 2023 3
13 Jul, 2023 3
13 Jul, 2023 3
13 Jul, 2023 3
13 Jul, 2023 CERT
11 Jul, 2023 8-A12B
11 Jul, 2023 CORRESP
11 Jul, 2023 CORRESP
10 Jul, 2023 CORRESP
10 Jul, 2023 S-1/A
6 Jul, 2023 SEC STAFF
6 Jul, 2023 UPLOAD
3 Jul, 2023 S-1/A
23 Jun, 2023 S-1
15 May, 2023 SEC STAFF
11 May, 2023 DRS/A
10 May, 2023 DRSLTR
25 Apr, 2023 DRS/A
25 Apr, 2023 DRSLTR
20 Apr, 2023 UPLOAD
24 Mar, 2023 DRS
21 Mar, 2022 RW
10 May, 2021 S-1/A
16 Apr, 2021 S-1
11 Mar, 2021 DRS
5 Jan, 2021 D
Last update:2024-03-06 12:23:30.502429
Sagimet Biosciences Inc. by TradingView

Sign Up to Subscribe